Yoda Pharmaceuticals Inc. (TPEX:7829)

Market Cap	3.66B
Revenue (ttm)	n/a
Net Income	-407.22M
EPS	-5.14
Shares Out	79.39M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	169,184
Open	41.85
Previous Close	43.45
Day's Range	41.85 - 46.15
52-Week Range	32.65 - 77.60
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	May 27, 2026

About Yoda Pharmaceuticals

Yoda Pharmaceuticals Inc., an AI-driven company, focuses on development of drugs targeting central nervous system disorders. The company’s flagship drug, YA-101 is in Phase 2 clinical trial for the treatment of multiple system atrophy. It is also involved in the development pipeline includes drugs in the field of neurological and psychiatric disorders and cerebrovascular diseases, targeting conditions, such as schizophrenia, Alzheimer's disease, Parkinson‘s disease, Autism, ischemic stroke, and traumatic brain injury. Yoda Pharmaceuticals Inc. ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2019
• Country: Cayman Islands
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7829